Offerings

Delayed 55s

Equity and debt offerings as they're announced.

Signed out · Sign up for real-time

Updates arrive automatically.

  • PT Freeport Indonesia Prices U.S.$750.0 Million of Senior Notes
    PR·

    PT Freeport Indonesia Prices U.S.$750.0 Million of Senior Notes

    PT Freeport Indonesia ("PTFI" or the "Company") announced today that it has agreed to sell (the "Notes Offering") U.S.$750.0 million of 6.90% senior notes due 2033 (the "Notes") priced at par of their principal amount. The Notes are expected to be rated "Baa3" by Moody’s and "BBB" by Fitch. The sale of the Notes is expected to settle on November 24, 2026, subject to customary closing conditions. PTFI intends to use the net proceeds from the Notes Offering to refinance existing indebtedness and for general corporate purposes. Interest on the Notes will be payable semi-annually in arrears on May 24 and November 24 of each year, beginning on May 24, 2027. The Notes will mature on Novembe

  • reAlpha (Nasdaq: AIRE) Reports Third-Quarter 2026 Financial Results
    PR·

    reAlpha (Nasdaq: AIRE) Reports Third-Quarter 2026 Financial Results

    reAlpha Tech Corp. (NASDAQ:AIRE) (the "Company" or "reAlpha"), an AI-powered real estate technology company, today announced financial results and business highlights for the third quarter ended September 30, 2026. Financial Highlights (All figures are approximate and compared to the third quarter of 2025 unless otherwise stated.) Revenue totaled approximately $1.6 million in the third quarter of 2026, compared to approximately $1.4 million in the third quarter of 2025, an increase of approximately 11%. Homebuying Services Segment revenue was approximately $1.3 million, compared to approximately $1.0 million in the prior-year period, an in

  • CORRECTING and REPLACING Ardent Health Announces Proposed Secondary Offering of Common Stock and Concurrent Share Repurchase
    PR·

    CORRECTING and REPLACING Ardent Health Announces Proposed Secondary Offering of Common Stock and Concurrent Share Repurchase

    Please replace the release with the following corrected version due to multiple revisions. The updated release reads: ARDENT HEALTH ANNOUNCES PROPOSED SECONDARY OFFERING OF COMMON STOCK AND CONCURRENT SHARE REPURCHASE Ardent Health, Inc. (NYSE:ARDT) ("Ardent Health" or the "Company") today announced the commencement of a proposed secondary public offering (the "Offering") of 8,000,000 shares of its common stock, consisting of 7,136,719 shares of its common stock by an affiliate of Equity Group Investments and 863,281 shares of its common stock by an affiliate of Ventas, Inc. (together, the "Selling Stockholders"). In connection with the Offering, the Selling Stockholders intend to gra

  • Restaurant Brands International Inc. Announces Pricing of Senior Secured Notes Offering
    PR·

    Restaurant Brands International Inc. Announces Pricing of Senior Secured Notes Offering

    Restaurant Brands International Inc. ("RBI") (NYSE:QSR) (TSX:QSR) (TSX:QSP), 1011778 B.C. Unlimited Liability Company (the "Issuer") and New Red Finance, Inc. (together with the Issuer, the "Issuers") announced today that the Issuers have priced a public offering (the "Offering") of $500 million aggregate principal amount of 6.00% Senior Secured Notes due 2031 (the "2031 Notes") and $500 million aggregate principal amount of 6.40% Senior Secured Notes due 2036 (together with the 2031 Notes, the "Notes"). The closing of the Offering is expected to occur on or about November 24, 2026, subject to customary closing conditions.

  • Ardent Health Announces Proposed Secondary Offering of Common Stock and Concurrent Share Repurchase
    PR·

    Ardent Health Announces Proposed Secondary Offering of Common Stock and Concurrent Share Repurchase

    Ardent Health, Inc. (NYSE:ARDT) ("Ardent Health" or the "Company") today announced the commencement of a proposed secondary public offering (the "Offering") of 6,244,629 shares of its common stock by an affiliate of Equity Group Investments and 755,371 shares of its common stock by an affiliate of Ventas, Inc. (together, the "Selling Stockholders"). In connection with the Offering, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. Subject to the completion of the Offering, the Company intends to concurrently repurchase from

  • SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering
    PR·

    SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering

    SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock. SELLAS intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock under the same terms and conditions. All of the shares in the offering will be sold by SELLAS. The offering is subject to market and other conditions, and there can be no assurance as to wheth

  • Millicom (Tigo) announces proposed Offering of Senior Notes due 2033
    PR·

    Millicom (Tigo) announces proposed Offering of Senior Notes due 2033

    Millicom (Tigo) announces proposed Offering of Senior Notes due 2033 Luxembourg, November 17, 2026 – Millicom International Cellular S.A. ("Millicom") today announced that it is commencing a private offering of Senior Notes due 2033 (the "Notes") that is exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). Millicom expects to use the proceeds from the issuance of the Notes, together with cash on hand, to (i) fund the purchase of any and all of Millicom’s outstanding 6.250% senior notes due 2029 (the "6.250% Notes") validly tendered and accepted for purchase in a concurrent tender offer (the "Tender Offer"), (ii) redeem any 6.250% Notes

  • Controlled Thermal Resources Appoints BBVA to Lead $420 Million Stage 1 Power Project Debt Financing
    PR·

    Controlled Thermal Resources Appoints BBVA to Lead $420 Million Stage 1 Power Project Debt Financing

    Controlled Thermal Resources Holdings Inc. ("CTR" or the "Company") today announced that it has appointed BBVA, a leading global financial group, as financial advisor to assist in structuring, arranging and syndicating the approximately $420 million debt financing for Stage 1 Power at its Hell’s Kitchen project in Imperial County, California. Stage 1 Power is a planned 50 MW baseload geothermal power facility on the northern extension of the Salton Sea Known Geothermal Resource Area, a field that has generated electricity since 1982. It is the first phase of the Hell’s Kitchen power build-out, targeted for commercial operation in the fir

  • Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering
    PR·

    Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering

    Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) ("iMDx," "we," "us," "our," or the "Company") today announced the pricing of its underwritten public offering of 8,296,429 shares of its common stock at a price to the public of $1.75 per share and pre-funded warrants to purchase up to 275,000 shares of common stock at a price to the public of $1.7499 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants in the offering are being sold by iMDx. In addition, the Company has gran

  • BP p.l.c. Launches Cash Tender Offers for USD Notes for Aggregate Purchase Consideration of Up to $6 Billion
    PR·

    BP p.l.c. Launches Cash Tender Offers for USD Notes for Aggregate Purchase Consideration of Up to $6 Billion

    BP p.l.c. ("BP") (NYSE:BP) (LSE: BP) today announced the commencement by its wholly-owned subsidiaries BP Capital Markets America Inc. ("BPCMA") and BP Capital Markets p.l.c. ("BPCM" and, together with BPCMA, the "Offerors" and each an "Offeror") of sixteen concurrent and separate offers (each, a "Tender Offer" and collectively, the "Tender Offers") to purchase for cash any and all of the outstanding notes of the series listed in the table below (collectively, the "Notes"), subject to the Maximum Purchase Condition (as defined below). The Tender Offers are being made upon the terms and subject to the conditions set forth in the offer to purchase da

  • ITT Appoints Blaine Browers as Chief Financial Officer
    PR·

    ITT Appoints Blaine Browers as Chief Financial Officer

    November 17, 2026-- ITT Inc. (NYSE: ITT), a leading manufacturer of highly engineered critical components and customized technology solutions, today announced the appointment of Blaine Browers as Senior Vice President and Chief Financial Officer, effective January 1, 2027. Browers will report to Chief Executive Officer and President Luca Savi. He succeeds Interim CFO Michael Savinelli who will continue as Vice President, Finance, Chief Tax Officer, Treasurer and Assistant Secretary. Browers is a seasoned executive with more than two decades of experience leading financial organizations within global industrial businesses. He has a strong track record of improving profitability and strengt

  • Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026
    PR·

    Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026

    Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that two abstracts have been accepted for publication at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2026 along with two corresponding poster presentations. The SABCS 2026 will be held from December 8-11, 2026. The posters will be presented on December 9, 2026 during the poster sessions for ongoing clinical trials and late breaking abstracts, with bot

  • S&P Global Announces Pricing of Public Offering of $750,000,000 Senior Notes due 2031, $600,000,000 Senior Notes due 2034 and $650,000,000 Senior Notes due 2036
    PR·

    S&P Global Announces Pricing of Public Offering of $750,000,000 Senior Notes due 2031, $600,000,000 Senior Notes due 2034 and $650,000,000 Senior Notes due 2036

    S&P Global (NYSE:SPGI) (the "Company") today announced that it has priced a public offering of $750,000,000 aggregate principal amount of 5.600% senior notes due 2031, $600,000,000 aggregate principal amount of 5.800% senior notes due 2034 and $650,000,000 aggregate principal amount of 6.000% senior notes due 2036. BofA Securities, Inc., Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, Mizuho Securities USA LLC, Morgan Stanley & Co. LLC, UBS Securities LLC and Wells Fargo Securities, LLC are acting as joint book-running managers in connection with the offering.

  • Manulife announces Subordinated Debenture issue
    PR·

    Manulife announces Subordinated Debenture issue

    The prospectus supplement, the corresponding base shelf prospectus and any amendment thereto in connection with this offering will be accessible through SEDAR+ within two business days.

  • Hydrofarm Announces Third Quarter 2026 Results and Subsequent Elimination of Term Loan
    PR·

    Hydrofarm Announces Third Quarter 2026 Results and Subsequent Elimination of Term Loan

    Hydrofarm Holdings Group, Inc. ("Hydrofarm" or the "Company") (NASDAQ:HYFM), a leading independent manufacturer and distributor of branded supplies and equipment for controlled environment agriculture ("CEA"), today announced financial results for its third quarter ended September 30, 2026. Third Quarter Events and Comparison vs. Prior Year Period: Net sales decreased to $14.5 million compared to $29.4 million. Gross Profit Margin increased to 17.7% of net sales compared to 11.6%. Adjusted Gross Profit Margin(1) increased to 23.6% of net sales compared to 18.8%.SG&A expense and Adjusted SG&A(1) expense decreased by 51.4% a

  • Con Edison Announces Common Share Offering with a Forward Component
    PR·

    Con Edison Announces Common Share Offering with a Forward Component

    Consolidated Edison, Inc. (Con Edison) (NYSE:ED) today announced the public offering of 6,000,000 of its common shares. In connection with the forward sale agreement described below, the forward counterparty (as defined below) has agreed to borrow from third parties and sell such shares to BofA Securities, Inc., which is acting as the underwriter in connection with the offering. The underwriter may offer the common shares in transactions on the New York Stock Exchange LLC, in the over-the-counter market or through negotiated transactions at market prices or at negotiated prices. Pursuant to the forward sale agreement, Con Edison expects to issue and del

  • EPR Properties Announces Closing of $575.0 Million Convertible Senior Notes Offering
    PR·

    EPR Properties Announces Closing of $575.0 Million Convertible Senior Notes Offering

    EPR Properties (NYSE:EPR) (the "Company") today announced the closing of its previously announced private offering of $575.0 million aggregate principal amount of 4.5% convertible senior notes due 2032 (the "Notes") (the "Offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Offering represents the aggregate of both the previously announced offering of $500.0 million, as well as the full exercise of the $75.0 million option to purchase additional Notes granted by the Company to the initial purchasers of the Notes. In connection with the pricing of the Notes and the exercise

  • Insight Molecular Diagnostics Announces Proposed Public Offering
    PR·

    Insight Molecular Diagnostics Announces Proposed Public Offering

    Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) ("iMDx," "we," "us," "our," or the "Company") today announced that it has commenced an underwritten public offering of shares of its common stock, or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, the Company intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of common stock offered in the public offering (including shares issuable upon exercise of the pre-funded warrants). The proposed offering is subject to market and other conditions, and there can be n

  • Parabolic Technologies, Inc. Reports Third Quarter 2026 Financial Results
    PR·

    Parabolic Technologies, Inc. Reports Third Quarter 2026 Financial Results

    Revenue Up 106% Sequentially to $4.7 Million with ConnectAndSell Acquisition; Path to Cash Flow Breakeven in Q1 2027; Subsequent Public Offering Proceeds Used to Repay $11.6 Million of Debt Ahead of Schedule Management to Host Third Quarter 2026 Results Conference Call Today, November 16, 2026 at 4:30 p.m.

  • WRAP Reports 43% Nine-Month Revenue Growth; Highlights Ongoing Congressional, ATF and State Actions Supporting Non-Lethal Response
    PR·

    WRAP Reports 43% Nine-Month Revenue Growth; Highlights Ongoing Congressional, ATF and State Actions Supporting Non-Lethal Response

    Wrap Technologies, Inc. (NASDAQ:WRAP) ("Wrap" or the "Company"), a global leader in innovative public safety technologies, today announced financial and operating results for the third quarter ended September 30, 2026. Third quarter total revenue was $1.5 million, consistent with the prior-year period. For the first nine months of 2026, total revenue increased 43% year over year, led by growth in product sales, and the Company strengthened its balance sheet while advancing its WrapShield platform strategy. During the third quarter, the U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives ("ATF") classified the BolaWrap 150 as an instrument of re